Partner Headlines - INFI

  1. The Top Five Drug Launches Of 2013

    IBD
  2. UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on ...

    Benzinga
  3. Benzinga's Top Downgrades

    Benzinga
  4. Celgene's stock hits new high

    IBD
  5. Mid-Day Market Update: Sysco Shares Rise Following Merger with ...

    Benzinga
  6. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD
  7. Benzinga's Volume Movers

    Benzinga
  8. Infinity Reports Encouraging Phase 1 IPI-145 Data at ASH

    Benzinga
  9. Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ...

    Benzinga
  10. Infinity Announces Updated Phase 1 Data of IPI-145 in iNLH at ...

    Benzinga
  11. UPDATE: William Blair Initiates Coverage on Infinity Pharmaceuticals ...

    Benzinga
  12. Benzinga's Top Initiations

    Benzinga
  13. The Best Small Cap Performers of 2012

    Benzinga
  14. Stocks Hitting 52-Week Highs

    Benzinga
  15. Infinity Pharma Amends Millennium Deal for PI3K-Delta, Gamma

    Benzinga
  16. Infinity Announces Amended PI3K-Delta,Gamma Agreement with Millennium

    Benzinga
  17. Infinity Announces Closing of Public Offering and Exercise of ...

    Benzinga
  18. Stocks Hitting 52-Week Highs

    Benzinga
  19. Infinity Pharma Prices 5.696M Shares at $26.33

    Benzinga
  20. Mid-Afternoon Market Update: Markets Continue to Rise, Diamond ...

    Benzinga
  21. Infinity Pharma Shares Rebound Over $22 Following Phase I Data ...

    Benzinga
  22. UPDATE: Jefferies Downgrades Infinity Pharmaceuticals to Hold ...

    Benzinga
  23. INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q)

    GuruFocus
  24. Stocks Hitting 52-Week Highs

    Benzinga
  25. UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at ...

    Benzinga
  26. INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q)

    GuruFocus
  27. Health Care Sector Wrap

    FoxBusiness
  28. Synacor, American Capital Mortgage Investment Crp, Other Stocks ...

    FoxBusiness
  29. Infinity Pharmaceuticals Shuts Down Cancer Trials

    Benzinga
  30. Morning Market Losers

    Benzinga
  31. Benzinga's Top Pre-Market Losers

    Benzinga
  32. A Peek Into The Market Before The Trading Starts

    Benzinga
  33. UPDATE: Piper Jaffray Lowers PT on Infinity Pharmaceuticals to ...

    Benzinga
  34. Infinity Plummets on Disappointing Phase 2 Study

    Benzinga
  35. Piper Jaffray Lowers PT on Infinity Pharmaceuticals to $8

    Benzinga
  36. Infinity Reports Update from Phase 2 Study of Saridegib Plus ...

    Benzinga
  37. Infinity Reports New Data from Phase 1b Trial of Saridegib in ...

    Benzinga
Trading Center